scholarly journals Pathological complete response rate in hormone receptor-negative breast cancer treated with neoadjuvant FEC, followed by weekly paclitaxel administration: A retrospective study and review of the literature

2016 ◽  
Vol 11 (5) ◽  
pp. 3064-3070
Author(s):  
TAKAYOSHI KIBA ◽  
NAO MORII ◽  
HIROTOSHI TAKAHASHI ◽  
SHINJI OZAKI ◽  
MISAO ATSUMI ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Retrospective Study ◽  
Hormone Receptor ◽  
Response Rate ◽  
Pathological Complete Response ◽  
Complete Response Rate ◽  
Complete Response ◽  
Weekly Paclitaxel ◽  
Review Of The Literature

scholarly journals Combinational Treatment of Doxorubicin With Neoadjuvant Docetaxel for Different Subtypes of Patients With Breast Cancer

2020 ◽  
Vol 19 ◽  
pp. 153303382092843
Author(s):  
Ling-Cheng Wang ◽  
Ling-Sheng Wang ◽  
Ai-Xia Li ◽  
Zhen-Zong Shi ◽  
Ya-Qiong Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Response Rate ◽  
Pathological Complete Response ◽  
Complete Response Rate ◽  
Molecular Subtypes ◽  
Complete Response ◽  
Luminal A ◽  
Ki 67 ◽  
Luminal B ◽  
Combinational Treatment

Aim: The aim of this study is to characterize the effect of chemotherapy drug doxorubicin with neoadjuvant drug docetaxel for different molecular subtypes. Methods: A total of 83 patients with late-stage breast cancer were chosen to undergo treatment and compared to these patients to the combinational treatment to identify the molecular characteristics that can predict the responses. Results: Total response rate is 81.9% (68/83 patients). Among them, 7 patients show pathological complete response of 8.4%, 12 patients show clinical complete response of 14.5%, 49 patients show partial response of 59%, and 15 patients show stable disease of 18.1%. The comparison among different subtypes of breast cancer, including luminal A, luminal B, basal-like, and ERBB2+ subtypes, did not show statistical significant differences to the treatment of combinational treatment for the complete response rate, including pathological complete response and clinical complete response. Comparing with luminal A and luminal B subtypes, the ERBB2+ and basal-like subtypes have better complete response and response rate rates. The disease-free survival rate and overall survival rate at 29 months after treatment did not show statistical significant differences among different subtypes of patients with breast cancer. Conclusion: The molecular subtypes of breast cancer can predict responses to the combinational treatment of doxorubicin with docetaxel, and ERBB2+ and basal-like subtypes have better response rate and complete response rate. There is correlation of estrogen receptor and KI-67 level changes with response rate as well, where KI-67 high patients are more sensitive to the treatment.

Sign in / Sign up

Export Citation Format

Share Document